Benchmarking Survey: Can we reduce procurement time in HEOR & RWE?

As healthcare moves towards an increased focus on outcomes and value, health economics & outcomes research (HEOR) and real-world evidence (RWE) are being used to guide value-based decisions, improve outcomes, reduce costs, and achieve market access. This move toward new… Continue Reading

CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America

Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, CVS Caremark announced in August that it would allow self-funded insurers to exclude from their plan any drug launched at… Continue Reading

HEOR Salaries: Big Growth in Certain Sectors. Where Do You Stand?

2017 HEOR & Market Access Salaries show big growth in key areas of Pricing, Market Access, and HEOR-focused Medical Communications. Just-released results from the bi-annual Global Salary Survey for HEOR & Market Access by HealthEconomics.Com show that 2017 median annual base salaries,… Continue Reading

Big Ideas for Big Data Analytics in Real-World Evidence: Insights from Dr. Rich Gliklich, CEO of OM1

  Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Dr. Rich Gliklich, CEO of OM1, to discuss how big data analytics are changing the face of real world evidence (RWE). The mission of this Cambridge, Massachusetts digital health company… Continue Reading